Groww Logo
Home>US Stocks>Amgen Inc.

Amgen Inc.

Healthcare
$245.35
+ $1.48 (0.61%) 1D
1D
1W
1M
1Y
3Y
5Y

Performance

Today’s Low
$
    Today’s High
    $
    52W Low
    $
      52W High
      $
      Open PricePrev. CloseVolumeAvg. Volume
      $245.14$243.872,344,0903,173,675

      Fundamentals

      Market Cap$131.06B
      P/B Ratio143.1
      P/E Ratio22.9
      Enterprise Value$161.39B
      Div. Yield3.18%
      Book Value1.67
      EPS(TTM)2.69
      ROENA
      Understand Fundamentals

      About the Company

      Amgen, Inc. is a multinational biopharmaceutical company headquartered in California, United States. It was established in the year 1980 as Applied Molecular Genetics, Inc. AMGN shares began trading on the Nasdaq Stock Market in 1983. As of 2020, the
      Amgen, Inc. is a multinational biopharmaceutical company headquartered in California, United States. It was established in the year 1980 as Applied Molecular Genetics, Inc. AMGN shares began trading on the Nasdaq Stock Market in 1983. As of 2020, the company ranked 162nd on Forbes’ list of Global 2000 and 135th on the Fortune 500. Forbes also named Amgen in its Just 100 2021– the list of 100 companies leading a new era of responsible capitalism. Amgen’s net worth is valued at $136.81 billion in 2020. AMGN is one of the world’s leading biotechnology companies, with a history of developing medications for serious and fatal illnesses. In 1989, Amgen received approval by the US Food and Drug Administration (FDA) for its product - Epogen. Epogen is used to treat anaemia caused by treatment with certain HIV drugs, chemotherapy for cancer, and chronic kidney failure. In 1991, FDA approved its drug Neupogen, which prevents infections in cancer patients undergoing chemotherapy. The company acquired Immunex Corporation in a $16 billion deal in 2009. With this acquisition, Amgen added Enbrel to its drug portfolio, the first drug for rheumatoid arthritis. Amgen stock made a significant jump of 2.8% to $241.60 on November 11th 2020, after its drug – Tezepelumab scored a Phase III win in the treatment of severe and uncontrolled asthma. In addition to innovative medicines, the company also undertakes transformative research and biologics manufacturing. Amgen’s migraine treatment was named as one of the Best Inventions of 2018 by TIME Magazine. In 2019, Amgen scored a perfect 100% on Human Rights Campaign Foundation’s Corporate Equality Index. That year, it was also named as one of the happiest companies in America by CareerBliss, for the fourth consecutive year. Amgen also holds a Guinness World Record for most osteoporosis screenings in a day. Amgen Foundation, its philanthropic entity, seeks to enrich communities by advancing excellence in science education, social services, environmental programs, culture and arts.
      ...Read more
      OrganisationAmgen Inc.
      IndustryDrug Manufacturers—General
      HeadQuartersThousand Oaks, CA

      Company Financials

      *All values are in Million $
      No Graph Data To Display
      Quarterly
      Yearly
      See Details

      FAQs on Amgen Inc.

      Can I Buy Amgen Inc. Shares in India?

      Yes, Amgen Inc. shares can be bought in India by opening an international trading account with Groww.

      How to Buy Amgen Inc. Shares in India?

      One can easily invest in Amgen Inc. shares from India by: Direct Investment - Opening an international trading account with Groww which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Amgen Inc. shares. Indirect Investment - Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Amgen Inc..

      What is the Share Price of Amgen Inc.?

      The share price of Amgen Inc. is in Dollars and if you are investing from India, you can always check the INR valuation before investing. The current Amgen Inc. share price is $245.35 as of 17 May ‘22

      What is the Market Cap of Amgen Inc.?

      The Amgen Inc. market cap is $131.06B as of 17 May ‘22

      What is the PE and PB ratio of Amgen Inc.?

      The PE and PB ratio of Amgen Inc. is 22.9 and 143.1 as of 17 May ‘22
      ⓒ 2016-2022 Groww. All rights reserved, Built with in India
      MOST POPULAR ON GROWWVERSION - 2.3.8
      STOCK MARKET INDICES:  S&P BSE SENSEX |  S&P BSE 100 |  NIFTY 100 |  NIFTY 50 |  NIFTY MIDCAP 100 |  NIFTY BANK |  NIFTY NEXT 50
      MUTUAL FUNDS COMPANIES:  ICICI PRUDENTIAL |  HDFC |  NIPPON INDIA |  ADITYA BIRLA SUN LIFE |  SBI |  UTI |  FRANKLIN TEMPLETON |  KOTAK MAHINDRA |  IDFC |  DSP |  AXIS |  TATA |  L&T |  SUNDARAM |  PGIM |  INVESCO |  LIC |  JM FINANCIAL |  BARODA PIONEER |  CANARA ROBECO |  HSBC |  IDBI |  INDIABULLS |  MOTILAL OSWAL |  BNP PARIBAS |  MIRAE ASSET |  PRINCIPAL |  BOI AXA |  UNION KBC |  TAURUS |  EDELWEISS |  NAVI |  MAHINDRA |  QUANTUM |  PPFAS |  IIFL |  Quant |  SHRIRAM |  SAHARA |  ITI

      ABOUT GROWW